Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

A newly developed radiolabeled antibody that targets the cancer antigen IL13Rα2 has been found to be highly specific, binding ...